Literature DB >> 20368232

Lipoprotein-associated phospholipase A2, C-reactive protein, and coronary artery disease in individuals with type 1 diabetes and macroalbuminuria.

Rachel G Miller1, Tina Costacou, Trevor J Orchard.   

Abstract

Given the paucity of data in type 1 diabetes concerning lipoprotein-associated phospholipase A( 2) (Lp-PLA(2)), we examined its prospective relationship with coronary artery disease (CAD), as well as the effect of modification by C-reactive protein (CRP) and haptoglobin genotype, in individuals with type 1 diabetes who are at an increased risk for CAD due to also having macroalbuminuria (n=96). Although Lp-PLA(2) activity was univariately predictive of CAD (HR=1.54 per SD, p=0.009), this relationship was not significant after covariate adjustment (p=0.59). There was a significant interaction between Lp-PLA(2) and CRP (p=0.02), i.e. those with both markers greater than the median level were more likely to have a CAD event than those persons with low levels of both (HR=2.89, p=0.06). When stratified by haptoglobin genotype, Lp-PLA(2) was predictive of CAD in persons with the 2/1 (HR=2.40, p=0.05), but not 2/2 (HR=0.66, p=0.27), genotype. The association between Lp-PLA(2) activity and CAD differs by CRP and haptoglobin genotype in this group of persons with type 1 diabetes and macroalbuminuria.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20368232      PMCID: PMC2858394          DOI: 10.1177/1479164109346358

Source DB:  PubMed          Journal:  Diab Vasc Dis Res        ISSN: 1479-1641            Impact factor:   3.291


  58 in total

1.  The 30-year natural history of type 1 diabetes complications: the Pittsburgh Epidemiology of Diabetes Complications Study experience.

Authors:  Georgia Pambianco; Tina Costacou; Demetrius Ellis; Dorothy J Becker; Ronald Klein; Trevor J Orchard
Journal:  Diabetes       Date:  2006-05       Impact factor: 9.461

2.  Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease.

Authors:  M J Caslake; C J Packard; K E Suckling; S D Holmes; P Chamberlain; C H Macphee
Journal:  Atherosclerosis       Date:  2000-06       Impact factor: 5.162

3.  C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.

Authors:  P M Ridker; C H Hennekens; J E Buring; N Rifai
Journal:  N Engl J Med       Date:  2000-03-23       Impact factor: 91.245

4.  Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses.

Authors:  J Danesh; P Whincup; M Walker; L Lennon; A Thomson; P Appleby; J R Gallimore; M B Pepys
Journal:  BMJ       Date:  2000-07-22

5.  A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women.

Authors:  G J Blake; N Dada; J C Fox; J E Manson; P M Ridker
Journal:  J Am Coll Cardiol       Date:  2001-11-01       Impact factor: 24.094

6.  Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice.

Authors:  R Quarck; B De Geest; D Stengel; A Mertens; M Lox; G Theilmeier; C Michiels; M Raes; H Bult; D Collen; P Van Veldhoven; E Ninio; P Holvoet
Journal:  Circulation       Date:  2001-05-22       Impact factor: 29.690

7.  Inhibition of lipoprotein-associated phospholipase A2 diminishes the death-inducing effects of oxidised LDL on human monocyte-macrophages.

Authors:  K L Carpenter; I F Dennis; I R Challis; D P Osborn; C H Macphee; D S Leake; M J Arends; M J Mitchinson
Journal:  FEBS Lett       Date:  2001-09-21       Impact factor: 4.124

8.  Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men.

Authors:  L E Rohde; C H Hennekens; P M Ridker
Journal:  Am J Cardiol       Date:  1999-11-01       Impact factor: 2.778

9.  Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group.

Authors:  C J Packard; D S O'Reilly; M J Caslake; A D McMahon; I Ford; J Cooney; C H Macphee; K E Suckling; M Krishna; F E Wilkinson; A Rumley; G D Lowe
Journal:  N Engl J Med       Date:  2000-10-19       Impact factor: 91.245

10.  C-reactive protein, cardiovascular risk factors, and mortality in a prospective study in the elderly.

Authors:  T E Strandberg; R S Tilvis
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-04       Impact factor: 8.311

View more
  9 in total

Review 1.  Cardiovascular risk assessment and screening in diabetes.

Authors:  Yanglu Zhao
Journal:  Cardiovasc Endocrinol       Date:  2017-02-15

2.  The inhibition of lipoprotein-associated phospholipase A2 exerts beneficial effects against atherosclerosis in LDLR-deficient mice.

Authors:  Miao-miao Hu; Jie Zhang; Wen-yi Wang; Wen-yu Wu; Yan-ling Ma; Wei-hai Chen; Yi-ping Wang
Journal:  Acta Pharmacol Sin       Date:  2011-08-15       Impact factor: 6.150

Review 3.  Cardiovascular Disease in Adults with Type 1 Diabetes: Looking Beyond Glycemic Control.

Authors:  Rachel G Miller; Tina Costacou
Journal:  Curr Cardiol Rep       Date:  2022-08-10       Impact factor: 3.955

4.  Systematic Review of the Association between Lipoprotein-Associated Phospholipase A2 and Atherosclerosis.

Authors:  Jing Liu; Yuling Hong; Yue Qi; Fan Zhao; Dong Zhao
Journal:  N Am J Med Sci (Boston)       Date:  2011-10

5.  Diabetes and cardiovascular disease.

Authors:  Zachary T Bloomgarden
Journal:  Diabetes Care       Date:  2011-03       Impact factor: 19.112

Review 6.  Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association.

Authors:  Sarah D de Ferranti; Ian H de Boer; Vivian Fonseca; Caroline S Fox; Sherita Hill Golden; Carl J Lavie; Sheela N Magge; Nikolaus Marx; Darren K McGuire; Trevor J Orchard; Bernard Zinman; Robert H Eckel
Journal:  Diabetes Care       Date:  2014-08-11       Impact factor: 19.112

7.  Association between high-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2 and carotid atherosclerosis: A cross-sectional study.

Authors:  Huamin Liu; Yan Yao; Youxin Wang; Long Ji; Kai Zhu; Haitao Hu; Jianxin Chen; Jichun Yang; Qinghua Cui; Bin Geng; Qing Liu; Dong Li; Yong Zhou
Journal:  J Cell Mol Med       Date:  2018-08-09       Impact factor: 5.310

8.  Associations between epicardial adipose tissue, subclinical atherosclerosis and high-density lipoprotein composition in type 1 diabetes.

Authors:  Cristina Colom; David Viladés; Montserrat Pérez-Cuellar; Rubén Leta; Andrea Rivas-Urbina; Gemma Carreras; Jordi Ordóñez-Llanos; Antonio Pérez; Jose Luis Sánchez-Quesada
Journal:  Cardiovasc Diabetol       Date:  2018-12-07       Impact factor: 9.951

9.  Prospective association between inflammatory markers and progression of coronary artery calcification in adults with and without type 1 diabetes.

Authors:  Amy C Alman; Gregory L Kinney; Russell P Tracy; David M Maahs; John E Hokanson; Marian J Rewers; Janet K Snell-Bergeon
Journal:  Diabetes Care       Date:  2013-01-22       Impact factor: 19.112

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.